Tan Weichu, Zhu Yitong, Chen Siting
Department of Laboratory Medicine, Medical Research Center of Nanfang Hospital, School of Basic Medical Sciences, Guangdong Provincial Key Laboratory of Precision Medical Diagnostics, Guangdong Provincial Key Laboratory of Single-Cell and Extracellular Vesicles, Guangdong Engineering and Technology Research Center for Rapid Diagnostic Biosensors, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, People's Republic of China.
The Affiliated Qingyuan Hospital (Qingyuan People's Hospital), Guangzhou Medical University, Qingyuan, Guangdong, 511518, People's Republic of China.
Lipids Health Dis. 2025 Apr 28;24(1):160. doi: 10.1186/s12944-025-02578-7.
Malignant tumors represent a significant worldwide health challenge, with elevated morbidity and mortality rates necessitating enhanced early identification and individualized treatment. Liposomes, as biomimetic lipid-based nanovesicles, have developed as a multifaceted platform for detecting and treating malignant tumors due to their excellent biocompatibility, stability, and membrane fusion properties. Circulating tumor markers, such as circulating tumor cells (CTCs), extracellular vesicles (EVs), circulating tumor proteins (CTPs), and circulating tumor nucleic acids (ctNAs), play a key role in early cancer diagnosis, disease progression monitoring, and personalized therapy. Liposome-based platforms enable effective molecular recognition, targeted detection, and signal amplification by targeting circulating tumor biomarkers, significantly increasing the potential for early tumor diagnosis and treatment. This review systematically summarizes advancements in the study of liposomes concerning circulating tumor markers, including applications in targeted recognition, early detection, and disease diagnosis, while discussing present problems and prospective applications of existing technology.
恶性肿瘤是全球重大的健康挑战，其发病率和死亡率不断上升，因此需要加强早期识别和个性化治疗。脂质体作为基于脂质的仿生纳米囊泡，由于其优异的生物相容性、稳定性和膜融合特性，已发展成为一个用于检测和治疗恶性肿瘤的多面平台。循环肿瘤标志物，如循环肿瘤细胞（CTC）、细胞外囊泡（EV）、循环肿瘤蛋白（CTP）和循环肿瘤核酸（ctNA），在癌症早期诊断、疾病进展监测和个性化治疗中发挥着关键作用。基于脂质体的平台通过靶向循环肿瘤生物标志物实现有效的分子识别、靶向检测和信号放大，显著提高了早期肿瘤诊断和治疗的潜力。本文系统总结了脂质体在循环肿瘤标志物研究方面的进展，包括在靶向识别、早期检测和疾病诊断中的应用，同时讨论了现有技术目前存在的问题和未来的应用前景。
